The historical rank and industry rank for Lee's Pharmaceutical Holdings's Net Margin % or its related term are showing as below:
FRA:L1PA'
s Net Margin % Range Over the Past 10 Years
Min: 1.59 Med: 10.47 Max: 156.95
Current: 6.4
FRA:L1PA's Net Margin % is ranked better than 53.03% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs FRA:L1PA: 6.40
Lee's Pharmaceutical Holdings (FRA:L1PA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Lee's Pharmaceutical Holdings Net Margin % Related Terms
Lee's Pharmaceutical Holdings Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lee's Pharmaceutical Holdings Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Lee's Pharmaceutical Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lee's Pharmaceutical Holdings (FRA:L1PA) has a Net Margin % of 3.34% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Lee's Pharmaceutical Holdings and its competitors. This is 68% below median its historical median of 10.47. Over the past decade, Lee's Pharmaceutical Holdings' Net Margin % has ranged from 1.59 to 156.95. According to the industry distribution chart, Lee's Pharmaceutical Holdings ranks #449 out of 956 companies in the Drug Manufacturers industry, placing it in the top 47%.
Is Lee's Pharmaceutical Holdings' Net Margin % too high?
Lee's Pharmaceutical Holdings' current Net Margin % of 3.34% is 68% below median its 10-year median of 10.47. Over the past 10 years, this metric has ranged from a low of 1.59 to a high of 156.95. The Drug Manufacturers industry median Net Margin % is 5.56. Lee's Pharmaceutical Holdings' value of 3.34% is 39.9% below this industry median. Based on the distribution chart, Lee's Pharmaceutical Holdings ranks #449 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lee's Pharmaceutical Holdings ranks #449 out of 956 companies for Net Margin %. This puts Lee's Pharmaceutical Holdings in the upper half of its industry. The industry median Net Margin % is 5.56. Lee's Pharmaceutical Holdings' value of 3.34% is 39.9% below this benchmark. Historically, Lee's Pharmaceutical Holdings' own Net Margin % has ranged from 1.59 to 156.95 over the past decade. While the company's 10-year median is 10.47 vs. the industry median of 5.56, Lee's Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lee's Pharmaceutical Holdings's current Net Margin % of 3.34% is 39.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Lee's Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lee's Pharmaceutical Holdings's current Net Margin % is 3.34%, which is 68% below median its own 10-year median of 10.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (FRA:L1PA) has a current Net Margin % of 3.34%. The stock's GF Value™ is €0.17, compared to a current price of €0.11 — trading 37.1% below its estimated fair value. The current Net Margin % is 3.34%, which is 68% below median its 10-year median of 10.47 and 39.9% below the Drug Manufacturers industry median of 5.56. Lee's Pharmaceutical Holdings' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (FRA:L1PA), the current Net Margin % is 3.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lee's Pharmaceutical Holdings (FRA:L1PA) Overvalued in 2026?
Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of €0.11 is trading 37.1% below its estimated GF Value™ of €0.17.
Key valuation signals for FRA:L1PA:
Net Margin %: 3.34% (68% below median its 10-year median of 10.47)
GF Value™: €0.17 vs. price of €0.11 (37.1% below fair value)
Industry Position: 39.9% below the Drug Manufacturers median (#449 of 956)
No single metric tells the full story. See the FRA:L1PA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lee's Pharmaceutical Holdings Business Description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score
Get the complete analysis for FRA:L1PA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L1PA has been successfully added to your 
